Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
- Conditions
- Chronic Iron Overload
- Interventions
- Other: Iron chelator
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 489
- Registration Number
- NCT05440487
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT05432388
- Locations
- 🇺🇸
Western Sky Medical Research, El Paso, Texas, United States
🇺🇸Allergy Associates of Utah, Sandy, Utah, United States
🇺🇸Seattle Allergy and Asthma Rsch, Seattle, Washington, United States
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT05429502
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
🇺🇸Levine Childrens Hospital, Charlotte, North Carolina, United States
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05424523
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
- Conditions
- Polycythemia Vera (PV)
- Interventions
- Other: Ruxolitinib
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1576
- Registration Number
- NCT05421104
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Special Drug Use-results Surveillance of Scemblix Tablets
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Other: Asciminib
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT05421091
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT05415072
- Locations
- 🇺🇸
Massachusetts General Hospital Hematology Oncology, Boston, Massachusetts, United States
🇺🇸Columbia University Medical Center- New York Presbyterian Onc Dept, New York, New York, United States
🇺🇸Memorial Sloane Kettering Cancer Center MSKCC, New York, New York, United States
Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery
- Conditions
- Post Operative Endophthalmitis
- Interventions
- Other: Moxifloxacin hydrochloride ophthalmic solution
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 102
- Registration Number
- NCT05413980
- Locations
- 🇮🇳
Novartis Investigative Site, Delhi, India
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
- Conditions
- Primary HypercholesterolemiaMixed Dyslipidemia
- Interventions
- Other: Inclisiran
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 855
- Registration Number
- NCT05399992
- Locations
- 🇬🇧
Novartis Investigative Site, Middlesex, United Kingdom
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
- Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT05397496
- Locations
- 🇺🇸
University Of Miami, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States